Pharming (PHAR) Liabilities and Shareholders Equity (2019 - 2026)

Pharming (PHAR) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $468.0 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity rose 4.87% year-over-year to $468.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 billion (up 15.29% YoY) and the FY2025 annual result came in at $500.0 million, up 25.0% from the prior year.
• Liabilities and Shareholders Equity slipped to $468.0 million in Q2 2026, from $489.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $382.3 billion in Q3 2022 to a low of $392.8 million in Q1 2022.
• A 5-year average of $21.7 billion and a median of $433.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The widest YoY moves for Liabilities and Shareholders Equity: up 106078.15% in 2022, down 99.91% in 2022.
• Tracing PHAR's Liabilities and Shareholders Equity over 5 years: stood at $425.8 million in 2022, then gained by 8.7% to $462.9 million in 2023, then declined by 13.58% to $400.0 million in 2024, then advanced by 25.0% to $500.0 million in 2025, then fell by 6.4% to $468.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $468.0 million (Q2 2026), $489.4 million (Q1 2026), and $500.0 million (Q4 2025), per Business Quant data.